Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Daehwa Pharma earns approval for world’s first oral anti-cancer drug
By 황유미Published : Sept. 9, 2016 - 17:35
[THE INVESTOR] Daehwa Pharmaceutical announced on Sept. 9 that its oral cancer treatment DHP107 has been granted approval for manufacturing and sales by the Ministry of Food and Drug Safety.
DHP107 is a modified version of paclitaxel, a therapy for breast, ovarian, lung and uterine cancers to be taken orally, a first of its kind in the world.
Paclitaxel had to be diluted before it was administered via intravenous injection. And steroids and antihistamine had to be administered to prevent possible allergic reaction, including shock and hyperventilating, to the diluents.
Oral intake is not only convenient for the patients but also will lessen the number of hospital visits, the company said.
Paclitaxel has a 4 trillion won (US$3.64 billion) market in the world and 30 billion won market in the country.
By Hwang You-mee (glamazon@heraldcorp.com)
DHP107 is a modified version of paclitaxel, a therapy for breast, ovarian, lung and uterine cancers to be taken orally, a first of its kind in the world.
Paclitaxel had to be diluted before it was administered via intravenous injection. And steroids and antihistamine had to be administered to prevent possible allergic reaction, including shock and hyperventilating, to the diluents.
Oral intake is not only convenient for the patients but also will lessen the number of hospital visits, the company said.
Paclitaxel has a 4 trillion won (US$3.64 billion) market in the world and 30 billion won market in the country.
By Hwang You-mee (glamazon@heraldcorp.com)
